Oral Microbiota and Muscle Function in the Ageing Subject
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age70+
SponsorUniversity Hospital, Rouen
About this trial
Ageing of the general population may be a risk factor for various complications, including sarcopenia. Sarcopenia is a progressive loss of muscle mass and muscle strength, leading to a decrease in functional capacities. It affects between 0.7% and 16% of European adults over 70 years of age (1). Recent studies suggest that the faecal microbiota may be altered with ageing but also according to sarcopenic status. Furthermore, no study has currently published data on the relationship between salivary microbiota and sarcopenic status. The main hypothesis of this study is that a decrease in salivary microbiota richness could be associated with impaired handgrip strength in the ageing subject.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male or female adult volunteer, over 70 years of age
Non-hospitalised
Having read and understood the information letter and signed the consent form
Affiliated with a Social Security scheme
Disqualifiers
Already included in an interventional drug clinical trial
Unable to understand and complete the questionnaires
Deprived of liberty by an administrative or judicial decision or protected adult subject (under guardianship, curatorship or judicial protection order)
Receiving antibiotic treatment or having received antibiotic treatment during the previous 3 months
Trial design
Design model
Single group
Treatments tested in this trial
Salivary and fecal microbiota sampling and muscle strength assessment
Procedure/SurgeryCollection of saliva and stool samples for microbiota analysis and assessment of handgrip strength in adults aged over 70 years.
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: Study ParticipantsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Salivary microbiota richness
Salivary microbiota richness (gene richness/alpha diversity) measured from saliva samples.
Time frame
baselineSecondary outcomes
1
Fecal microbiota diversity
Assessment of fecal microbiota diversity from stool samples and its association with maximal handgrip strength.
Time frame
15 days2
Title: Fecal microbiota richness
Assessment of fecal microbiota richness according to handgrip strength and sarcopenia status.
Time frame
15 days3
Salivary microbiota diversity
Assessment of salivary microbiota diversity from saliva samples and its association with maximal handgrip strength.
Time frame
15 days4
Fecal microbiota richness according to sarcopenia status
Comparison of fecal microbiota richness between participants with and without sarcopenia.
Time frame
15 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: